• Molecular NameRemoxipride
  • SynonymRemoxiprida [INN-Spanish]; Remoxipride [Usan:Ban:Inn]; Remoxipridum [INN-Latin]; Romoxipride
  • Weight371.275
  • Drugbank_IDDB00409
  • ACS_NO117591-79-4
  • Show 2D model
  • LogP (experiment)2.13
  • LogP (predicted, AB/LogP v2.0)2.62
  • pka8.9
  • LogD (pH=7, predicted)0.33
  • Solubility (experiment)0.074 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.33
  • LogSw (predicted, AB/LogsW2.0)0.17
  • Sw (mg/ml) (predicted, ACD/Labs)1.24
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds6
  • TPSA50.8
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA psychoactive drug and substituted benzamide which was a promising antipsychotic during clinical trials in the 1990s, but was removed due to possible side effects.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability90.0
  • Protein binding80.0
  • Volume of distribution (VD)0.5~0.7 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNo active metabolites
  • Half life4~7 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)LD50=820 (intraperitoneal)
  • LD50 (mouse)N/A